SEC Form 4 · accession 0000899243-18-031055
Corvus Pharmaceuticals, Inc. · CRVS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel W. Hunt
Officer — SVP, Chief Business Officer
Period of report
Dec 12, 2018
Accepted (ET)
Dec 14, 2018 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626971
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.94 | Dec 12, 2018 | A | 50,000 | D | — | Dec 12, 2028 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from December 12, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.